The Important Role of Preventive Screening in IBD: How, Who, and Does It Matter?Premiere Date: Monday, November 8, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, November 8, 2022
|Miguel Regueiro, MD, AGAF, FACG, FACP (Moderator)
Chair, Digestive Disease and Surgery
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
|Sara El Ouali, MD
Digestive Disease Institute at Cleveland Clinic
Abu Dhabi, United Arab Emirates
Clinical Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
|Florian Rieder, MD
Vice Department Chair
Co-Director, Inflammatory Bowel Diseases (IBD) Section
Director, IBD Advanced Fellowship
Department of Gastroenterology, Hepatology and Nutrition
Digestive Disease and Surgery Institute
Department of Inflammation and Immunity, Lerner Research Institute
Cleveland Clinic Foundation
While state-of-the-art treatment approaches have dramatically improved management of inflammatory bowel disease (IBD), health care disparities such as racial differences and socioeconomic status are a significant issue, increasing rates of complications, repeated hospitalizations, and procedures in patients with IBD. All members of the interdisciplinary team should be involved in coordinating such patients to avoid suboptimal management and treatment delays.
This CME Outfitters Live and OnDemand focuses on best practices for initiating interdisciplinary collaboration to provide medically underserved children, adolescents, and adults with IBD with guideline-recommended care.
At the end of this CE activity, participants should be able to:
- Integrate preventive screenings into practice to improve health outcomes in all patients with IBD.
- Initiate interdisciplinary collaboration to provide optimal care for patients with IBD.
Supported by educational grants from AbbVie Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Gastroenterologists, PAs, nurse practitioners, nurses, dietitians, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Regueiro receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on advisory boards and consults for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Dr. El Ouali has no disclosures to report.
Dr. Rieder reports that he receives grants and research support from AbbVie Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Crohn's and Colitis Foundation; Helmsley Charitable Trust; Kenneth Rainin Foundation; Morphic Therapeutic; National Institutes of Health (NIH); Pfizer Inc.; Pliant Therapeutics, Inc.; and UCB, Inc. He reports that he is a consultant for 89bio, Inc.; AbbVie Inc.; Adnovate; AgomAb Therapeutics; Allergan; Arena Pharmaceuticals, Inc.; Boehringer-Ingelheim; Celgene Corporation/Bristol Myers Squibb Company; Clinical Data Interchange Standards Consortium (CDISC); Cowen Inc.; Ferring Pharmaceuticals; Galmed Pharmaceuticals; Genentech, Inc.; Gilead Sciences, Inc.; Gossamer Bio; Guidepoint Global, LLC; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Koutif Therapeutics, LLC; The Leona M. and Harry B. Helmsley Charitable Trust; Mestag Therapeutics; Metacrine; Morphic Therapeutic; Organovo Holdings Inc.; Origo Biopharma; Pfizer Inc.; Pliant Therapeutics, Inc.; Prometheus Biosciences; Receptos; RedX Pharma; Roche; Samsung Biologics; Surmodics, Inc.; Surrozen; Takeda Pharmaceuticals U.S.A., Inc.; Techlab Inc.; Theravance Biopharma; Thetis Pharmaceuticals; UCB, Inc.; and Ysios.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
S. Michelle Franks, MSN, APRN, FNP-BC (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).